Price Table
* Prices are based on daily market changes.
Date | Open | High | Low | Close | Volume | Delivery % | 20-Day sma | 50-Day sma | 200-Day sma |
---|
View More
Day High Low Range
Time | Lowest | highest | Volume |
---|
Past Performance & Moving Averages
Day’s | Low high range | SMA | Stock performance | Nifty performance |
---|
PIVOT POINTS
NAME | S4 | S3 | S2 | S1 | PIVOT POINTS | R1 | R2 | R3 | R4 |
---|---|---|---|---|---|---|---|---|---|
CLASSIC | - | - | - | - | - | - | - | - | - |
WOODIE‘S | - | - | - | - | |||||
FIBONACCI | - | - | |||||||
CAMARILLA | - |
Trend Analysis
Key Data
Market cap | Book value | stock p/e | Dividend yield | roce | roe | sales growth (3Y) | face value (3Y) |
---|
Profile
Lupin limited or LUPIN
It is a transnational company that is engaged in the development of APIs, generic and branded formulations. It is the largest producer of Tuberculosis drugs in the world, having both onshore and offshore presence of its products in about 70 countries. Its manufacturing unit is located in Jammu, Goa, Tarapur, Ankleshwar, Mandideep, Indore, Aurangabad and Kyowa in Japan. All the manufacturing facilities of the company are being approved by several international regulatory agencies such as UK MHRA, US FDA, TGA Australia, WHO, and MCC South Africa.Some of the Business:
- In formulations, the company offers a broad spectrum of products for the treatment of CVS, Cephalosporins, CNS, Anti–Asthma, Anti–TB, Diabetology, Dermatology, GI, and more. Also, it constitutes 70% of Lupin’s business. It has its presence in countries such as Europe, the USA, Japan, Australia, and emerging markets of India and several other countries.
- In the APIs segment, the company provides the product offerings for the treatment of TB, Cardiovascular, Cephalosporins, and many more.
- In CRAMS or Contract Research and Manufacturing Services space, the company has acquired Novodigm that is engaged in developing and validating the products.
Some of the Awards:
- 2011:
- The Top Indian Pharma company under the ‘Pharmaceuticals’ sector for the Dun & Bradstreet – Rolta Corporate Awards in 2010.
- The Company was ranked among India's Top 3 'Best Companies to Work For' in Healthcare and Pharma Sector.
- The Hall of Fame Award by Chemtech Foundation (Leadership and Excellence Awards).
- IMM or Institute of Marketing and Management Award for Excellence as a Top Organization.
- The Company is ranked 2nd amongst India's 'Best Companies to Work for' in the Biotechnology and Pharmaceutical Sector.
- 2010:
- Received the Indian Pharmaceutical Company of the Year 2010' by Frost & Sullivan India Excellence in Healthcare Awards in 2010.
- The Best Drug Development Company in Asia' by The New Economy Pharmaceutical & Healthcare Awards in 2010.
- The Company receives 'The Most Promising Entrant into the Big League' by CNBC India Business Leader Awards in 2010.
- 2009:
- International Excellence Award by the Institute of Economic Studies.
- Exceptional Export Performance Award by Pharmexcil (A Pharmaceuticals Export Promotion Council of India).
- 2008:
- 'WalMart Supplier Award of Excellence' for overall commitment, on-time shipping, performance, innovative programs, and the overall partnership.
- 2007:
- Amerisource Bergen, as one of the leading wholesalers in the US conferred as the “Best New Manufacturer of the Year, Generics Rx” to the Company.
- The Cardinal Health conferred two awards – the “Trade Representative of the Year” and the “Quality Supplier Award” to the Company.
Some of the Milestones:
- 2014:
- The Company acquires Laboratories Grin S.A. De C.V., Mexico; Specialty Ophthalmic Company; and enters the Market of Latin America.
- The Company acquires Nanomi B.V. – enters the Complex Injectable Space.
- 2013:
- The inauguration of the new Plant located at Nagpur.
- 2012:
- The Company launches Generic Geodon Capsules".
- The Company launches Generic SEROQUEL Tablets.
- 2011:
- The Company acquires I'rom Pharmaceuticals via its Japanese Subsidiary.
- Both Lupin and Medicis Enter in a Joint Development Agreement.</